Analysis of tumor PD-L1 expression and biomarkers in relation to clinical activity in patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC) treated with nivolumab (NIVO) plus ipilimumab (IPI): CheckMate 142

被引：0

作者：

Andre, T. ^{[1
]}

Overman, M. ^{[2
]}

Lonardi, S. ^{[3
]}

Aglietta, M. ^{[4
,5
]}

McDermott, R. ^{[6
]}

Wong, K. Y. M. ^{[7
]}

Morse, M. ^{[8
]}

Hendlisz, A. ^{[9
]}

Moss, R. A. ^{[10
]}

Ledeine, J-M. ^{[11
]}

Tang, H. ^{[12
]}

Cao, Z. A. ^{[10
]}

Kopetz, S. ^{[13
]}

机构：

[1] Hop St Antoine, Med Oncol, Paris, France

[2] MD Anderson Canc Ctr, Gastrointestinal Med Oncol, Houston, TX USA

[3] Ist Oncol Veneto IRCCS, Med Oncol, Padua, Italy

[4] Inst Canc Res & Treatment, Div Med Oncol, Dept Oncol Sci, Candiolo, Italy

[5] Univ Torino, Med Sch, Turin, Italy

[6] St Vincents Univ Hosp, Med Oncol, Dublin, Ireland

[7] Univ Sydney, Sydney Med Sch, Med Oncol, Sydney, NSW, Australia

[8] Duke Univ, Off Res Adm, Dept Surg, Durham, NC USA

[9] Inst Jules Bordet, Oncol, Gastroenterol, Brussels, Belgium

[10] Bristol Myers Squibb, Res & Dev, Princeton, NJ USA

[11] Bristol Myers Squibb, Res & Dev, Braine Lalleud, Belgium

[12] Bristol Myers Squibb, Res & Dev, Princeton, NJ USA

[13] MD Anderson Canc Ctr, GI Med Oncol, Houston, TX USA

来源：

ANNALS OF ONCOLOGY | 2017年 / 28卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

484PD

引用

页数：1

共 50 条

[1] Combination of nivolumab (nivo) 1 ipilimumab (ipi) in the treatment of patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC): CheckMate 142 Study
Lonardi, S.
Andre, T.
Wong, K. Y. M.
Morse, M.
McDermott, R.
Hill, A.
Hendlisz, A.
Lenz, H.
Leach, J.
Moss, R. A.
Cao, Z. A.
Ledeine, J.
Kopetz, S.
Overman, M.
ANNALS OF ONCOLOGY, 2017, 28 : 3 - 3
[2] Combination of nivolumab (nivo) plus ipilimumab (ipi) in the treatment of patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC): CheckMate 142 study.
Andre, Thierry
Lonardi, Sara
Wong, Ka Yeung Mark
Morse, Michael
McDermott, Raymond S.
Hill, Andrew Graham
Hendlisz, Alain
Lenz, Heinz-Josef
Leach, Joseph W.
Moss, Rebecca Anne
Cao, Z. Alexander
Ledeine, Jean-Marie
Chan, Emily
Kopetz, Scott
Michael, J.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[3] Quality of life (QoL) in patients (pts) with microsatellite instability (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) treated with nivolumab (NIVO) alone or in combination with ipilimumab (IPI): CheckMate 142
Van Cutsem, E.
Dixon, M.
Taylor, F.
Sun, X.
Yip, C.
Blum, S. I.
ANNALS OF ONCOLOGY, 2021, 32 : S553 - S553
[4] Nivolumab (NIVO) ± ipilimumab (IPI) in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Five-year follow-up from CheckMate 142.
Overman, Michael J.
Lenz, Heinz-Josef
Andre, Thierry
Aglietta, Massimo
Wong, Mark Ka
Luppi, Gabriele
Van Cutsem, Eric
McDermott, Raymond S.
Hendlisz, Alain
Cardin, Dana Backlund
Morse, Michael
Neyns, Bart
Hill, Andrew Graham
Limon, M. Luisa
Garcia-Alfonso, Pilar
Krishnamurthy, Anuradha
Chen, Franklin
Abdullaev, Sandzhar
Soleymani, Samira
Lonardi, Sara
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[5] A phase 3 study of nivolumab (NIVO), NIVO plus ipilimumab (IPI), or chemotherapy for microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): CheckMate 8HW
Andre, T.
Van Cutsem, E.
Elez, E.
Bennouna, J.
de la Fouchardiere, C.
Yoshino, T.
Jensen, L.
Mendez, G.
Li, J.
Goekkurt, E.
Abdullaev, S.
Chen, T.
Lei, M.
Lonardi, S.
ANNALS OF ONCOLOGY, 2022, 33 : S250 - S250
[6] SAFETY PROFILE OF NIVOLUMAB plus IPILIMUMAB COMBINATION THERAPY IN PATIENTS WITH DNA MISMATCH REPAIR-DEFICIENT/MICROSATELLITE INSTABILITY-HIGH (DMMR/MSI-H) METASTATIC COLORECTAL CANCER (MCRC) IN CHECKMATE-142
Brutcher, Edith
Khoukaz, Taline
Hartman, Leighanne
ONCOLOGY NURSING FORUM, 2018, 45 (02)
[7] First results of nivolumab (NIVO) plus ipilimumab (IPI) vs NIVO monotherapy for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) from CheckMate 8HW.
Andre, Thierry
Elez, Elena
Lenz, Heinz-Josef
Jensen, Lars Henrik
Touchefeu, Yann
Van Cutsem, Eric
Garcia-Carbonero, Rocio
Tougeron, David
Mendez, Guillermo
Schenker, Michael
de la Fouchardiere, Christelle
Limon, Maria Luisa
Yoshino, Takayuki
Li, Jin
Aubin, Francine
Cela, Elvis
Chen, Tian
Lei, Ming
Jin, Lixian
Lonardi, Sara
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : LBA143 - LBA143
[8] A phase III study of nivolumab (NIVO), NIVO plus ipilimumab (IPI), or chemotherapy (CT) for microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): Checkmate 8HW
Abdullaev, Sandzhar
Andre, Thierry
Lei, Ming
Lenz, Heinz-Josef
Novotny, James
Paulson, Andrew Scott
Tejpar, Sabine
Yamazaki, Kentaro
Ledeine, Jean-Marie
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
[9] First-line (1L) nivolumab (NIVO) plus ipilimumab (IPI) in patients (pts) with microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): 64-month (mo) follow-up from CheckMate 142
Lenz, Heinz-Josef
Overman, Michael J.
Van Cutsem, Eric
Limon, Maria Luisa
Wong, Ka Yeung Mark
Hendlisz, Alain
Aglietta, Massimo
Garcia-Alfonso, Pilar
Neyns, Bart
Gelsomino, Fabio
Cardin, Dana Backlund
Dragovich, Tomislav
Shah, Usman
McCraith, Stephen
Wang, Rui
Lei, Ming
Yao, Jin
Jin, Lixian
Lonardi, Sara
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 97 - 97
[10] First-line (1L) nivolumab (NIVO) plus ipilimumab (IPI) in patients (pts) with microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): 64-month (mo) follow-up from CheckMate 142
Lenz, Heinz-Josef
Overman, Michael J.
Van Cutsem, Eric
Limon, M. Luisa
Wong, Mark Ka
Hendlisz, Alain
Aglietta, Massimo
Garcia-Alfonso, Pilar
Neyns, Bart
Gelsomino, Fabio
Cardin, Dana Backlund
Dragovich, Tomislav
Shah, Usman
McCraith, Stephen M.
Wang, Abigail
Lei, Ming
Yao, Jin
Jin, Lixian
Lonardi, Sara
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)

← 1 2 3 4 5 →